View More Recent Stories

Jun 26, 2025 04:08AM Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)
Jun 5, 2025 05:24AM Jefferies Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Jun 5, 2025 04:25AM Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)
May 29, 2025 08:36AM Rhythm Pharmaceuticals (RYTM) PT Raised to $94 at Stifel
May 14, 2025 08:03AM Rhythm Pharmaceuticals (RYTM) Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months
Apr 11, 2025 06:31AM Canaccord Genuity Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Apr 8, 2025 06:40AM Rhythm Pharmaceuticals (RYTM) PT Raised to $80 at H.C. Wainwright
Apr 8, 2025 06:37AM Rhythm Pharmaceuticals (RYTM) PT Raised to $92 at Canaccord Genuity
Apr 8, 2025 06:18AM Oppenheimer Reiterates Outperform Rating on Rhythm Pharmaceuticals (RYTM)
Apr 7, 2025 12:16PM BofA Securities Upgrades Rhythm Pharmaceuticals (RYTM) to Buy 'on valuation and lower risk'
Apr 7, 2025 07:27AM Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Apr 7, 2025 07:00AM Rhythm Pharmaceuticals (RYTM) Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction
Apr 1, 2025 06:17AM Wells Fargo Releases Regular Quarterly Update to Tactical Ideas List
Mar 27, 2025 04:35AM Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)
Mar 24, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Mar 20, 2025 04:09PM Rhythm Pharmaceuticals (RYTM) Reacquires Licensing Rights to IMCIVREE in China with Termination of Agreement with RareStone Ltd.
Mar 19, 2025 04:01PM Rhythm Pharmaceuticals (RYTM) Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Mar 18, 2025 07:07AM Rhythm Pharmaceuticals (RYTM) PT Raised to $66 at Needham
Mar 11, 2025 09:01AM Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Mar 6, 2025 04:38AM Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)
Mar 5, 2025 01:47PM Raymond James Reiterates Outperform Rating on Rhythm Pharmaceuticals (RYTM)
Mar 5, 2025 06:44AM Stifel Resumes Rhythm Pharmaceuticals (RYTM) at Buy
Mar 3, 2025 06:40AM Rhythm Pharmaceuticals (RYTM) PT Raised to $70 at H.C. Wainwright
Feb 28, 2025 07:58AM Rhythm Pharmaceuticals (RYTM) PT Raised to $94 at Guggenheim
Feb 27, 2025 06:54AM Rhythm Pharmaceuticals (RYTM) PT Raised to $81 at Canaccord Genuity
Feb 27, 2025 04:28AM Rhythm Pharmaceuticals (RYTM) PT Raised to $81 at Citizens JMP
Feb 26, 2025 07:14AM Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 2c
Feb 4, 2025 05:01AM Rhythm Pharmaceuticals (RYTM) PT Maintained at $75 at JMP Securities
Dec 20, 2024 02:16PM Rhythm Pharmaceuticals (RYTM) Announces FDA Approval of IMCIVREE for Patients as Young as 2 Years Old
Dec 20, 2024 06:22AM Oppenheimer Starts Rhythm Pharmaceuticals (RYTM) at Outperform
Dec 19, 2024 09:42AM Stifel Names Top Picks in Biotechnology 2025 Outlook Note
Dec 5, 2024 05:43AM Rhythm Pharmaceuticals (RYTM) PT Raised to $66 at Goldman Sachs
Nov 25, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Nov 6, 2024 09:05AM Rhythm Pharmaceuticals (RYTM) PT Raised to $65 at TD Cowen
Nov 6, 2024 07:12AM Rhythm Pharmaceuticals (RYTM) PT Raised to $64 at Needham
Nov 6, 2024 05:28AM Rhythm Pharmaceuticals (RYTM) PT Raised to $59 at Goldman Sachs
Nov 5, 2024 04:13PM Rhythm Pharmaceuticals (RYTM) Tops Q3 EPS by 7c
Oct 25, 2024 08:04AM H.C. Wainwright Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Oct 7, 2024 06:34AM H.C. Wainwright Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
Sep 17, 2024 01:55AM JMP Securities Starts Rhythm Pharmaceuticals (RYTM) at Market Outperform
Aug 26, 2024 08:02AM Rhythm Pharmaceuticals (RYTM) Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE in Patients as Young as 2 years old
Aug 7, 2024 07:03AM Rhythm Pharmaceuticals (RYTM) PT Lowered to $77 at Canaccord Genuity
Jul 31, 2024 09:11AM Rhythm Pharmaceuticals (RYTM) Announces European Commission Expands IMCIVREE Marketing Authorization to include Children as Young as 2 Years Old
Jul 25, 2024 07:39AM Rhythm Pharmaceuticals (RYTM) PT Raised to $55 at Needham
Jul 8, 2024 08:00AM Rhythm Pharmaceuticals (RYTM) Appoint Alastair Garfield as Chief Scientific Officer
Jun 28, 2024 08:01AM Rhythm Pharmaceuticals (RYTM) Receives Positive CHMP Opinion for IMCIVREE
Apr 5, 2024 01:00PM M&A watch: 3 biotech companies that are most likely to be acquired - Needham
View More Recent Stories